Clinical trial
Vaginal Progesterone to Reduce the Risk of Another Preterm Birth
NCT00086177 · Juniper Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00086177 |
|---|---|
| Title | Vaginal Progesterone to Reduce the Risk of Another Preterm Birth |
| Official title | A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy, Safety, and Tolerability of 8% Progesterone Vaginal Gel in Preventing Preterm Delivery in Pregnant Women at Increased-Risk for Preterm Delivery |
| Lead sponsor | Juniper Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pregnancy |
| Intervention type | Drug |
| Interventions | 8% progesterone vaginal gel, Placebo Vaginal Gel |
| Enrollment | 636 |
| Start date | Apr 1, 2004 |
| Primary completion | Jan 1, 2007 |
| Completion | Mar 1, 2009 |
| First posted | Jun 29, 2004 |
| Last update posted | Aug 19, 2010 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: